Calls
1
Sean Laaman
Head of U.S. Mid-Cap Biotech Equity Research, Morgan Stanley
Win Rate
100.0%
return
+2.6%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 16
$153.98
+2.6%
Although the regulatory environment has been quiet over the last six months, he expects faster passage of drugs to market as regulators try to keep up with China. This should benefit biotechnology by shortening development timelines and accelerating approvals.
Thematic ETFs
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Sean Laaman has 1 trade ideas tracked on Buzzberg across 1 tickers since September 2026. Most covered: XBI, AI-SECTOR, CHINA BIOTECHNOLOGY.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
